Last reviewed · How we verify
Kenalog 10
Kenalog 10 is a corticosteroid that suppresses inflammatory and immune responses by inhibiting inflammatory mediator release and immune cell activation.
Kenalog 10 is a corticosteroid that suppresses inflammatory and immune responses by inhibiting inflammatory mediator release and immune cell activation. Used for Intralesional treatment of inflammatory skin conditions (keloids, lichen planus, psoriasis plaques), Intra-articular injection for inflammatory arthritis and joint inflammation, Intradermal injection for alopecia areata and other localized inflammatory dermatoses.
At a glance
| Generic name | Kenalog 10 |
|---|---|
| Sponsor | The University of Western Australia |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Dermatology, Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone acetonide, the active ingredient in Kenalog 10, is a synthetic glucocorticoid that binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and modulates gene expression to reduce production of inflammatory cytokines, chemokines, and adhesion molecules. This results in decreased inflammation, reduced immune cell infiltration, and suppression of both humoral and cell-mediated immune responses. The 10 mg/mL formulation is typically used for intralesional or intra-articular injection.
Approved indications
- Intralesional treatment of inflammatory skin conditions (keloids, lichen planus, psoriasis plaques)
- Intra-articular injection for inflammatory arthritis and joint inflammation
- Intradermal injection for alopecia areata and other localized inflammatory dermatoses
Common side effects
- Local atrophy at injection site
- Skin depigmentation
- Local infection risk
- Systemic corticosteroid effects (with repeated injections)
Key clinical trials
- Dose Dependent Steroid Injections (PHASE4)
- USG-Guided Shoulder Injections in Frozen Shoulder (NA)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- The Additive Effect of Exercise in Addition to Corticosteroid Injection in Plantar Fasciitis (NA)
- A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder (PHASE4)
- Topical Cryotherapy and Keloid/Hypertrophic Scars (PHASE3)
- Effectiveness of Vitamin b12 Versus Kenalog on Traumatic Ulcer Associated With Orthodontic Treatment (NA)
- Effectiveness of Transcranial Magnetic Stimulation (TMS) in Smoking Cessation, Combining Withdrawal Stimulation Followed by Maintenance Stimulation to Prevent Relapse (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kenalog 10 CI brief — competitive landscape report
- Kenalog 10 updates RSS · CI watch RSS
- The University of Western Australia portfolio CI